Revolution Medicines

RVMD · Nasdaq · United States

Share price · RVMD

$159.82-56.18 (-26.01%) 3M

close as of 2026-11-18 · 24h delayed · vol 2.3M (1.0x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when RVMD's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 11 Nov 2026-6.4%
  2. 6 Nov 2026+8.2%
  3. 8 Oct 2026-6.3%
  4. 24 Sep 2026+4.8%
  5. 16 Sep 2026-4.4%
  6. 28 Apr 2026+10.0%
  7. 13 Apr 2026+41.3%
  8. 26 Jan 2026-16.9%

    Nothing announced by RVMD that day or the session before.

  9. 9 Jan 2026+10.5%
  10. 7 Jan 2026+28.6%

Share of unusual movement by asset

For each asset, the share of RVMD's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Daraxonrasib (Rasonque)
events and moves
2540%
Zoldonrasib
events and moves
94%
Elironrasib
events and moves
2shown from 8 days
RMC-5127
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—0%
Other company news (earnings, financing, releases naming no asset)—11%
Sessions with no dated event—45%

Assets

(5 total)
5Total Assets
1Approved
1Phase 3 / Filed
3Phase 1–2 / Early
3Diseases
Quick filter:
Showing 5 of 5 assets
Target & Modality
Daraxonrasib(Rasonque)
Approved
pan-RAS · RAS (pan-RAS, RAS-mutant tumors)Small molecule
Non-Small Cell Lung CancerPancreatic Ductal Adenocarcinoma
Phase 3
KRAS G12DSmall molecule
Non-Small Cell Lung CancerPancreatic Cancer
Phase 1/2
KRAS G12CSmall molecule
Non-Small Cell Lung Cancer
Phase 1
KRAS G12VSmall molecule
Non-Small Cell Lung Cancer
Phase 1
mTORC1 (mammalian target of rapamycin complex 1) (inhibitor)Small molecule
Non-Small Cell Lung Cancer

Upcoming events

(11 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (3)
May 2027 (1)
Daraxonrasib · RasonquePhase 1/2Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
Est. primary completion 2027-05-31 · NCT05379985 · CT.gov ↗
What to watch
June 2027 (1)
Elironrasib + Daraxonrasib · Rasonque + ZoldonrasibPhase 1/2Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV …
Est. primary completion 2027-06 · NCT06162221 · CT.gov ↗
What to watch
December 2027 (1)
Daraxonrasib · RasonquePhase 3NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma) …
Est. primary completion 2027-12-01 · NCT06881784 · CT.gov ↗
What to watch
2028 (4)
April 2028 (1)
Daraxonrasib · RasonquePhase 3Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC) …
Est. primary completion 2028-04 · NCT07491445 · CT.gov ↗
What to watch
September 2028 (1)
Daraxonrasib · Rasonque + ZoldonrasibPhase 1/2Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC, Gastrointestinal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma
Est. primary completion 2028-09-30 · NCT06445062 · CT.gov ↗
What to watch
December 2028 (2)
Elironrasib + Daraxonrasib · RasonquePhase 1/2Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
Est. primary completion 2028-12 · NCT06128551 · CT.gov ↗
What to watch
ZoldonrasibPhase 3Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC) …
Est. primary completion 2028-12-30 · NCT07621718 · CT.gov ↗
What to watch
2029 (4)
March 2029 (1)
Daraxonrasib · Rasonque + ZoldonrasibPhase 3Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC) …
Est. primary completion 2029-03 · NCT07805954 · CT.gov ↗
What to watch
May 2029 (2)
Elironrasib + Daraxonrasib · Rasonque + ZoldonrasibPhase 1/2Advanced Solid Tumors, Metastatic Solid Tumors, Non-small Cell Lung Cancer (NSCLC), NSCLC, Colorectal Cancer (CRC), CRC
Est. primary completion 2029-05 · NCT07397338 · CT.gov ↗
What to watch
Daraxonrasib · RasonquePhase 3Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC) …
Est. primary completion 2029-05-10 · NCT07252232 · CT.gov ↗
What to watch
October 2029 (1)
ZoldonrasibPhase 3NSCLC, Non-small Cell Lung Cancer, Non-Small Cell Lung Cancer NSCLC, Non-Squamous Non Small Cell Lung Cancer, Lung Cancer (NSCLC) …
Est. primary completion 2029-10 · NCT07777822 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

16 November 2026ApprovalDaraxonrasibEuropean Commission approves Rasonque in previously treated metastatic pancreatic adenocarcinoma
EU, European Commission · Source ↗
26 August 2026ApprovalDaraxonrasibFDA approves Rasonque (daraxonrasib) in metastatic pancreatic cancer
US, FDA · Source ↗
22 July 2026Filing acceptedDaraxonrasibFDA accepts the daraxonrasib NDA in previously treated metastatic pancreatic cancer
US, FDA · Revolution Medicines · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$198M$417M$616M+ $3.0B short-term inv.$407M-$416M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$395M$815M+ $3.1B short-term inv.$644M-$387M operating cash flowreport ↗
2026-Q1—$344M$441M+ $1.5B short-term inv.$454M-$354M operating cash flowreport ↗
2025-Q3—$263M$217M+ $1.7B short-term inv.$305M-$207M operating cash flowreport ↗
2025-Q2—$224M$402M+ $1.7B short-term inv.$248M-$222M operating cash flowreport ↗
2025-Q1—$206M$334M+ $1.8B short-term inv.$213M-$194M operating cash flowreport ↗
2024-Q3$0$152M$201M+ $1.3B short-term inv.$156M-$130M operating cash flowreport ↗
2024-Q2$0$135M$276M+ $1.3B short-term inv.$133M-$128M operating cash flowreport ↗
2024-Q1$0$118M$288M+ $1.4B short-term inv.$116M-$161M operating cash flowreport ↗
2023-Q3$0$108M$358M+ $455M short-term inv.$108M-$101M operating cash flowreport ↗
2023-Q2$3.8M$98M$380M+ $529M short-term inv.$98M-$67M operating cash flowreport ↗
2023-Q1$7.0M$69M$427M+ $483M short-term inv.$68M-$62M operating cash flowreport ↗
2022-Q3$3.4M$69M$179M+ $476M short-term inv.$73M-$52M operating cash flowreport ↗
2022-Q2$9.1M$61M$106M+ $356M short-term inv.$61M-$56M operating cash flowreport ↗
2022-Q1$7.6M$56M$98M+ $421M short-term inv.$58M-$55M operating cash flowreport ↗
2021-Q3$1.1M$46M$129M+ $480M short-term inv.$53M-$37M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$0$987M$384M+ $1.6B short-term inv.$283M-$898M operating cash flowreport ↗

Revolution Medicines reported FY2025 revenue of $0M, flat YoY, with R&D expenses of $987.3M, up 66.7% YoY from $592.2M. Cash, cash equivalents and marketable securities were $2.0B as of December 31, 2025, including a $250M royalty monetization tranche received in June 2025. The company posted a full-year net loss of $1.1B versus $600.1M in 2024, and a fourth-quarter net loss of $364.9M versus $194.6M.

The company guided FY2026 GAAP operating expenses to $1.6B–$1.7B, including non-cash stock-based compensation of $180M–$200M. Clinically, it expects a RASolute 302 Phase 3 readout for daraxonrasib in second-line metastatic pancreatic cancer in the first half of 2026, expects to substantially complete enrollment in RASolve 301 in previously treated NSCLC this year, initiated RASolute 305 for zoldonrasib in first-line G12D-mutant pancreatic cancer, and plans further Phase 3 starts including RASolute 309 and RASolve 308. It also dosed the first patient with RMC-5127, reported encouraging initial zoldonrasib plus FOLFIRINOX data, disclosed collaborations with Summit, Tango, and Bristol Myers Squibb, and received FDA Breakthrough Therapy designation for zoldonrasib.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$0$592M$543M+ $1.7B short-term inv.$150M-$557M operating cash flowreport ↗
2023-FY$12M$423M$696M+ $1.2B short-term inv.$109M-$351M operating cash flowreport ↗
2022-FY$35M$253M$161M+ $484M short-term inv.$62M-$224M operating cash flowreport ↗
2021-FY$29M$187M$109M+ $469M short-term inv.$47M-$147M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 172 sales ($159.6M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-16Kelsey Stephen Michael · See RemarksOption exercise27,160$18.56$504KForm 4
2026-11-16Kelsey Stephen Michael · See RemarksOpen-market sale11,542$166.75$1.9MForm 4
2026-11-16Kelsey Stephen Michael · See RemarksOpen-market sale3,627$167.66$608KForm 4
2026-11-16Kelsey Stephen Michael · See RemarksOpen-market sale8,039$168.64$1.4MForm 4
2026-11-16Kelsey Stephen Michael · See RemarksOpen-market sale3,052$169.46$517KForm 4
2026-11-16Kelsey Stephen Michael · See RemarksOpen-market sale700$170.40$119KForm 4
2026-11-16Kelsey Stephen Michael · See RemarksOpen-market sale200$171.65$34KForm 4
2026-11-16Kelsey Stephen Michael · See RemarksOption exercise (derivative)27,160——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 508 reporting institutions held 198.5M shares ($18.6B, 91.8% of shares outstanding).

#InstitutionSharesValue
1FARALLON CAPITAL MANAGEMENT LLC13,604,796$1.3B
2BlackRock, Inc.11,212,706$1.1B
3JANUS HENDERSON GROUP PLC9,766,496$949.5M
4BAKER BROS. ADVISORS LP9,555,357$929.3M
5FMR LLC8,464,314$823.2M
6VANGUARD CAPITAL MANAGEMENT LLC8,362,284$813.2M
7Nextech Invest, Ltd.7,601,087$739.2M
8VANGUARD PORTFOLIO MANAGEMENT LLC7,502,623$729.6M
9Paradigm Biocapital Advisors LP6,655,703$647.3M
10WELLINGTON MANAGEMENT GROUP LLP6,027,819$586.2M
11ADAGE CAPITAL PARTNERS GP, L.L.C.5,475,611$532.5M
12STATE STREET CORP4,402,662$428.2M
13UBS Group AG4,386,791$426.6M
14GEODE CAPITAL MANAGEMENT, LLC3,338,142$323.9M
15Alphabet Inc.3,292,525$320.2M